(Q42213684)

18 October 2017

Cyclophosphamide-induced bladder toxicity in wegener's granulomatosis (English)

1 reference

https://api.crossref.org/works/10.1002/ART.1780310402

31 December 2022

1 reference

https://api.crossref.org/works/10.1002/ART.1780310402

31 December 2022

1 reference

https://api.crossref.org/works/10.1002/ART.1780310402

31 December 2022

author name string

Benson RC Jr

2

1 reference

18 October 2017

T. J. Stillwell

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A3358809

31 December 2022

R. C. Benson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A3358809

31 December 2022

R. A. DeRemee

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A3358809

31 December 2022

T. J. McDonald

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A3358809

31 December 2022

L. H. Weiland

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A3358809

31 December 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=3358809

31 December 2022

publication date

1 April 1988

1 reference

full work available at URL

18 October 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fart.1780310402

1 reference

https://api.crossref.org/works/10.1002/ART.1780310402

https://onlinelibrary.wiley.com/doi/full/10.1002/art.1780310402

31 December 2022

1 reference

https://api.crossref.org/works/10.1002/ART.1780310402

31 December 2022

published in

Arthritis & Rheumatology

1 reference

18 October 2017

Arthritis and Rheumatism

31

4

465–70

April 1988

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=3358809

31 December 2022

volume

31

1 reference

18 October 2017

465-470

1 reference

18 October 2017

4

1 reference

Wegener's Granulomatosis: Prospective Clinical and Therapeutic Experience With 85 Patients for 21 Years

18 October 2017

1 reference

https://api.crossref.org/works/10.1002%2FART.1780310402

Immunosuppressive and Cytotoxic Chemotherapy: Long-Term Complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FART.1780310402

Bladder Complications in Patients Receiving Cyclophosphamide for Systemic Lupus Erythematosus or Rheumatoid Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FART.1780310402

Water intoxication in man after cyclophosphamide therapy. Time course and relation to drug activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FART.1780310402

Treatment of cyclophosphamide-induced cystitis with prostaglandin E2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FART.1780310402

Comparison of mesna with forced diuresis to prevent cyclophosphamide induced haemorrhagic cystitis in marrow transplantation: a prospective randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FART.1780310402

Cyclophosphamide Therapy in Wegener's Granulomatosis

21 January 2018

1

1 reference

https://api.crossref.org/works/10.1002/ART.1780310402

Wegener's granulomatosis. Long-term followup of patients treated with cyclophosphamide

31 December 2022

2

1 reference

https://api.crossref.org/works/10.1002/ART.1780310402

Major problems in internal medicine

31 December 2022

3

21

72

Cupps

1981

1 reference

https://api.crossref.org/works/10.1002/ART.1780310402

Bladder cancer following administration of cyclophosphamide

31 December 2022

7

1 reference

https://api.crossref.org/works/10.1002/ART.1780310402

Urinary-bladder fibrosis and telangiectasia associated with long-term cyclophosphamide therapy

31 December 2022

8

1 reference

https://api.crossref.org/works/10.1002/ART.1780310402

Urinary bladder tumors following cyclophosphamide therapy: a report of two cases with a review of the literature

31 December 2022

9

1 reference

https://api.crossref.org/works/10.1002/ART.1780310402

Bladder Toxicity With Chronic Oral Cyclophosphamide Therapy in Nonmalignant Disease

31 December 2022

10

1 reference

https://api.crossref.org/works/10.1002/ART.1780310402

Controlled trial of cyclophosphamide in rheumatoid arthritis

31 December 2022

11

1 reference

https://api.crossref.org/works/10.1002/ART.1780310402

Bladder malignancy in a patient receiving low dose cyclophosphamide for treatment of rheumatoid arthritis

31 December 2022

12

1 reference

https://api.crossref.org/works/10.1002/ART.1780310402

Carcinoma of the bladder in a patient treated with cyclophosphamide for rheumatoid arthritis

31 December 2022

13

1 reference

https://api.crossref.org/works/10.1002/ART.1780310402

Cyclophosphamide cystitis—Identification of acrolein as the causative agent

31 December 2022

14

1 reference

https://api.crossref.org/works/10.1002/ART.1780310402

Cyclophosphamide hemorrhagic cystitis requiring urinary diversion

31 December 2022

18

1 reference

https://api.crossref.org/works/10.1002/ART.1780310402

The Incidence Of Bladder Cancer after Cyclophosphamide Therapy

31 December 2022

20

1 reference

https://api.crossref.org/works/10.1002/ART.1780310402

Carcinoma of the Bladder complicating Cyclophosphamide Therapy

31 December 2022

21

1 reference

https://api.crossref.org/works/10.1002/ART.1780310402

Cyclophosphamide-induced hemorrhagic cystitis. A review of 100 patients

31 December 2022

22

1 reference

https://api.crossref.org/works/10.1002/ART.1780310402

Leimyosarcoma of the urinary bladder. 13 years after cyclophosphamide therapy for Hodgkin's disease

31 December 2022

24

1 reference

https://api.crossref.org/works/10.1002/ART.1780310402

Uroepithelial Carcinoma in Association With Cyclophosphamide Ingestion

31 December 2022

25

1 reference

https://api.crossref.org/works/10.1002/ART.1780310402

Transitional cell carcinoma of the ureter associated with cyclophosphamide therapy for benign disease: a case report

31 December 2022

26

1 reference

https://api.crossref.org/works/10.1002/ART.1780310402

CYTOLOGICAL STUDY OF THE EFFECT OF CYCLOPHOSPHAMIDE ON THE EPITHELIUM OF THE URINARY BLADDER IN MAN

31 December 2022

27

1 reference

https://api.crossref.org/works/10.1002/ART.1780310402

Urinary complications of cyclophosphamide therapy: etiology, prevention, and management

31 December 2022

28

1 reference

https://api.crossref.org/works/10.1002/ART.1780310402

Prevention of cyclophosphamide-induced hemorrhagic cystitis

31 December 2022

30

1 reference

https://api.crossref.org/works/10.1002/ART.1780310402

Journal of the National Cancer Institute

31 December 2022

32

47

223

Primack

1971

1 reference

https://api.crossref.org/works/10.1002/ART.1780310402

The Effect of N-Acetyl Cysteine on Cyclophosphamide Cystitis

31 December 2022

33

1 reference

https://api.crossref.org/works/10.1002/ART.1780310402

Successful management of radiation cystitis with sodium pentosanpolysulfate

31 December 2022

36

1 reference

https://api.crossref.org/works/10.1002/ART.1780310402

Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma

31 December 2022

37

1 reference

https://api.crossref.org/works/10.1002/ART.1780310402

The use of sodium 2-mercaptoethane sulfonate to prevent cyclophosphamide cystitis.

31 December 2022

39

1 reference

https://api.crossref.org/works/10.1002/ART.1780310402

31 December 2022

Identifiers

1 reference

18 October 2017

1 reference